​
​

Entrada Therapeutics (TRDA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Entrada Therapeutics Revenue Highlights

Latest Revenue (Y)

$129.01M

Latest Revenue (Q)

$19.57M

Main Segment (Y)

License

Entrada Therapeutics Revenue by Period

Entrada Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$129.01M100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Entrada Therapeutics generated $129.01M in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Entrada Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$19.57M-79.33%
2024-06-30$94.69M60.17%
2024-03-31$59.12M41.27%
2023-12-31$41.85M-4.31%
2023-09-30$43.73M140.70%
2023-06-30$18.17M-28.07%
2023-03-31$25.26M100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Entrada Therapeutics generated $19.57M in revenue during Q3 2024, up -79.33% compared to the previous quarter, and up 107.71% compared to the same period a year ago.

Entrada Therapeutics Revenue Breakdown

Entrada Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23
License$139.00M

Entrada Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23
License$53.90M$70.90M$157.90M-$211.60M--
Upfront Payment Revenue----$39.80M$14.63M-

Entrada Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License (100.00%).

Entrada Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
TRDAEntrada Therapeutics$129.01M$19.57M
MOLNMolecular Partners$7.04M$2.74M
CNTACentessa Pharmaceuticals$6.88M-
CRNXCrinetics Pharmaceuticals$4.01M-
OPTOpthea$108.41K$61.27K
CGEMCullinan Oncology--
PHVSPharvaris--
RLYBRallybio-$299.00K
IRONDisc Medicine--
ELYMEliem Therapeutics--
PMVPPMV Pharmaceuticals--
LRMRLarimar Therapeutics--
PRDSPardes Biosciences--
VIGLVigil Neuroscience--
THRDThird Harmonic Bio--
GLUEMonte Rosa Therapeutics-$4.70M
EWTXEdgewise Therapeutics--
GNTAGenenta Science S.p.A.--
PEPGPepGen--
TYRATyra Biosciences--

TRDA Revenue FAQ

What is Entrada Therapeutics’s yearly revenue?

Entrada Therapeutics's yearly revenue for 2023 was $129.01M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. TRDA's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

What is Entrada Therapeutics’s quarterly revenue?

Entrada Therapeutics's quarterly revenue for Q3 2024 was $19.57M, a -79.33% decrease from the previous quarter (Q2 2024), and a -55.25% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $94.69M, a 60.17% increase from the previous quarter (Q1 2024), and a 421.16% increase year-over-year (Q2 2023). TRDA's quarterly revenue for Q1 2024 was $59.12M, a 41.27% increase from the previous quarter (Q4 2023), and a 134.05% increase year-over-year (Q1 2023).

What is Entrada Therapeutics’s revenue growth rate?

Entrada Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.

What are Entrada Therapeutics’s revenue streams?

Entrada Therapeutics's revenue streams in c 23 are License

What is Entrada Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Entrada Therapeutics was License. This segment made a revenue of $139M, representing 100.00% of the company's total revenue.